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Abstract
Background: To our knowledge, no reports are available indicating the effects of synbiotic supplementation on
hormonal status, biomarkers of inflammation and oxidative stress in subjects with polycystic ovary syndrome
(PCOS). This research was done to assess the effects of synbiotic supplementation on hormonal status, biomarkers
of inflammation and oxidative stress in subjects with PCOS.
Methods: This randomized double-blind, placebo-controlled trial was conducted on 60 subjects diagnosed with
PCOS according to the Rotterdam criteria. Subjects were randomly assigned into two groups to take either
synbiotic (n = 30) or placebo (n = 30) for 12 weeks. Endocrine, inflammation and oxidative stress biomarkers were
quantified at baseline and after the 12-week intervention.
Results: After the 12-week intervention, compared with the placebo, synbiotic supplementation significantly
increased serum sex hormone-binding globulin (SHBG) (changes from baseline in synbiotic group: + 19.8 ± 47.3 vs.
in placebo group: + 0.5 ± 5.4 nmol/L, p = 0.01), plasma nitric oxide (NO) (changes from baseline in synbiotic group:
+ 5.5 ± 4.8 vs. in placebo group: + 0.3 ± 9.1 μmol/L, p = 0.006), and decreased modified Ferriman Gallwey (mF-G)
scores (changes from baseline in synbiotic group: − 1.3 ± 2.5 vs. in placebo group: − 0.1 ± 0.5, p = 0.01) and serum
high-sensitivity C-reactive protein (hs-CRP) (changes from baseline in synbiotic group: − 950.0 ± 2246.6 vs. in
placebo group: + 335.3 ± 2466.9 ng/mL, p = 0.02). We did not observe any significant effect of synbiotic
supplementation on other hormonal status and biomarkers of oxidative stress.
Conclusions: Overall, synbiotic supplementation for 12 weeks in PCOS women had beneficial effects on SHBG,
mFG scores, hs-CRP and NO levels, but did not affect other hormonal status and biomarkers of oxidative stress.
Trial registration: This study was retrospectively registered in the Iranian website (www.irct.ir) for registration of
clinical trials (IRCT201509115623N53), on 2015–09-27.
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Background
Polycystic ovary syndrome (PCOS) is a common
gynecological endocrine disorder related to irregular
menstrual cycles and androgen excess affecting 6–12%
of premenopausal women [1]. It was reported that sev-
eral pro-inflammatory factors and mediators increase in
subjects with PCOS, including C-reactive protein (CRP),
leukocytes, cytokines, and reactive oxygen species [2].
Inflammation and oxidative stress are associated with
obesity, type 2 diabetes mellitus (T2DM), hyperandro-
genemia, insulin resistance as well as an increased risk
of cardiovascular disease (CVD) [3].
Nowadays, there is a growing interest to use synbiotics
and probiotics in diseases related to metabolic syndrome
[4]. The basis of this interest derives mostly from the
results of nutritional intervention studies suggest that
synbiotics intake have beneficial effects on metabolic
profiles, biomarkers of inflammation and oxidative stress
among patients with gestational diabetes (GDM) [5],
T2DM [6] and cancer [7]. In addition, gut microbiota
may participate in the whole-body metabolism by affect-
ing energy balance, insulin metabolism and inflamma-
tion related to metabolic disorders [8]. We have
previously shown that consumption of the synbiotic
bread for 8 weeks among participants with T2DM had
beneficial effects on plasma nitric oxide (NO) and mal-
ondialdehyde (MDA) concentrations, but did not influ-
ence plasma total antioxidant capacity (TAC) and
glutathione (GSH) values [9]. In another study by Ipar et
al. [10], it was seen that synbiotic supplementation for
30 days in obese children had beneficial effects on lipid
fractions and total oxidative stress. However, multi-
species probiotics supplementation (1010 CFU/day) for
14 weeks did not affect biomarkers of inflammation and
oxidative stress among trained men [11].
Synbiotics and probiotics may affect metabolic param-
eters through the effect on the production of short chain
fatty acid (SCFA), decreased gene expression of inflam-
matory factors [12], and increased synthesis of GSH,
apoptosis induction and up-regulation of oxidative pen-
tose pathway activity [13]. To our knowledge, no reports
are available indicating the effects of synbiotic supple-
mentation on hormonal, inflammatory and oxidative pa-
rameters in subjects with PCOS. The objective of this
study was to evaluate the effects of synbiotic supplemen-
tation on hormonal, inflammatory and oxidative parame-
ters in these patients.
Methods
Trial design and participants
This randomized, double-blinded, placebo-controlled
clinical trial, registered in the Iranian clinical trials web-
site at: (http://www.irct.ir: IRCT201509115623N53).
This study was conducted among 60 women with PCOS
diagnosed according to the Rotterdam criteria [14, 15], aged
18–40 years who referred to the Kossar Clinic in Arak,
Iran, from April to June 2016. Main exclusion criteria
were: smokers, taking probiotic and/or synbiotic supple-
ments, pregnant women, endocrine diseases including
thyroid, diabetes and/or impaired glucose tolerance as
well as gastrointestinal problems in the study.
Ethics approval and consent to participate
The study was followed the Declaration of Helsinki
guideline and was approved by the ethics committee of
the Arak University of Medical Sciences (AUMS), Arak,
Iran. Informed consent was taken from all subjects.
Study protocol
At first, women were randomly allocated to receive ei-
ther synbiotic supplements or placebo (n = 30 each
group) for 12 weeks. Duration of the treatment was
selected based on observed beneficial effects of probiotic
supplementation on metabolic profiles in women with
PCOS [16]. Randomization was done using computer-
generated random numbers by a trained staff at the
gynecology clinic. Randomization and allocation were
concealed to the researchers and participants until the
final analyses were completed. Synbiotic supplements
were containing Lactobacillus acidophilus, Lactobacillus
casei and Bifidobacterium bifidum (2 × 109 CFU/g each)
plus 0.8 g inulin. Synbiotic supplements and the placebo
were manufactured by Tak Gen Zist Pharmaceutical
Company (Tehran, Iran) and Barij Essence
Pharmaceutical Company (Kashan, Iran), respectively.
The compliance rate during the intervention was
monitored by a brief daily cell phone reminder to take the
supplement and asking the subjects to return the
supplement containers. All participants completed a 3-
days food record and physical activity records as metabolic
equivalents (METs) prior to intervention, at weeks 3, 6, 9
and 12 of the treatment. Daily macro- and micro-nutrient
intakes were calculated by analyzing food data using nutri-
tionist IV software (First Databank, San Bruno, CA) [17].
Anthropometric parameters
Anthropometric measurements were determined in a
fasting status using a standard scale (Seca, Hamburg,
Germany) at baseline and after the 12-week treatment.
Body mass index (BMI) was calculated as weight in kg
divided by height in meters squared.
Clinical assessments
Clinical parameters included determinations of hirsutism
using a mFG scoring system [18].
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Biochemical evaluation
At pre- and post-treatment, 10 mL blood were collected
from each subject at Arak reference laboratory. Hormo-
nal profiles were determined using an Elisa kits (DiaMe-
tra, Milano, Italy) with inter- and intra-assay coefficient
variances (CVs) lower than 7%. Free androgen index
(FAI) was calculated based on suggested formulas. High
sensitivity C-reactive protein (hs-CRP) and insulin values
were assessed by ELISA kits (LDN, Nordhorn, Germany)
and (Monobind, California, USA), respectively. The
plasma NO [19], TAC [20], GSH [21] and MDA levels
[22] were determined by the spectrophotometric method
with inter- and intra-assay CVs less than 5%. To deter-
mine fasting plasma glucose, we used Pars Azmun kit,
Tehran, Iran. The homeostatic model of assessment for
insulin resistance (HOMA-IR) was determined accord-
ing to suggested formulas [23].
Sample size
We used a randomized clinical trial sample size formula
with type one (α) and type two errors (β) to be 0.05 and
the power of 80% to calculate sample size. Based on a
previous study [24], we used a standard deviation (SD)
of 283.7 ng/mL and a difference in mean (d) of 230.
0 ng/mL, considering hs-CRP levels as the key variable.
According to the calculation 25 women should be en-
rolled in each group. Assuming a dropout of 5 subjects
per group, the final sample size was considered to be 30
per treatment group.
Statistical methods
The Kolmogorov-Smirnov test was performed to deter-
mine the normality of data. Outcome log-transformation
was used if model residual has non-normal distribution
(hs-CRP, MDA, SHBG and FAI). To detect differences in
anthropometric parameters as well as in macro- and
micro-nutrient intakes between the two groups, we ap-
plied independent t-test. To assess the effects of synbio-
tic supplementation on metabolic parameters, we used
one-way repeated measures analysis of variance. Adjust-
ment for changes in baseline values of biochemical pa-
rameters, age and baseline BMI was performed by
analysis of covariance (ANCOVA). P-values < 0.05 were
considered statistically significant. All statistical analyses
were done using the Statistical Package for Social Sci-
ence version 18 (SPSS Inc., Chicago, Illinois, USA).
Results
In this study, all 60 subjects [synbiotic and placebo (n =
30 each group)] completed the trial (Fig. 1). The compli-
ance rate in this study was high; more than 90% of cap-
sules were taken during the course of the trial in both
groups. No side effects were reported following the in-
take of synbiotic supplements in patients with PCOS.
Fig. 1 Summary of patient flow diagram
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Mean age, height, and weight, BMI and METs at base-
line and end-of-trial were not statistically different be-
tween the two groups (Table 1).
No significant difference in mean dietary macro- and
micro-nutrient intakes between the two groups was seen
(Data not shown).
Compared with the placebo, synbiotic supplementation
significantly increased serum sex hormone-binding globu-
lin (SHBG) (changes from baseline in synbiotic group: +
19.8 ± 47.3 vs. in placebo group: + 0.5 ± 5.4 nmol/L, p = 0.
01), plasma NO (changes from baseline in synbiotic group:
+ 5.5 ± 4.8 vs. in placebo group: + 0.3 ± 9.1 μmol/L, p = 0.
006), and decreased mF-G scores (changes from baseline
in synbiotic group: − 1.3 ± 2.5 vs. in placebo group: − 0.1 ±
0.5, p = 0.01), FAI (changes from baseline in synbiotic
group: − 0.12 ± 0.29 vs. in placebo group: − 0.01 ± 0.08, p
= 0.01) and serum hs-CRP (changes from baseline in syn-
biotic group: − 950.0 ± 2246.6 vs. in placebo group: + 335.
3 ± 2466.9 ng/mL, p = 0.02) (Table 2). In addition, com-
pared with the placebo, synbiotic supplementation re-
sulted in a significant reduction in serum insulin levels
(changes from baseline in synbiotic group: − 1.6 ± 2.9 vs.
in placebo group: + 0.4 ± 2.3 μIU/mL, p = 0.003), HOMA-
IR (changes from baseline in synbiotic group: − 0.4 ± 0.7
vs. in placebo group: + 0.1 ± 0.5, p = 0.003). A trend to-
ward a greater decrease in total testosterone (changes
from baseline in synbiotic group: − 0.4 vs. in placebo
group: − 0.1 ng/mL, p = 0.09) and plasma MDA concen-
trations (changes from baseline in synbiotic group: − 0.2 ±
0.1 vs. in placebo group: + 0.5 ± 1.4 μmol/L, p = 0.05) was
observed in synbiotic group compared with placebo
group. We did not observe any significant effect of
Table 1 General characteristics of study participants
Placebo group (n = 30) Synbiotic group (n = 30) pa
Age (y) 25.9 ± 5.2 25.7 ± 5.5 0.90
Height (cm) 163.3 ± 6.6 161.4 ± 5.8 0.25
Weight at study baseline (kg) 72.4 ± 14.1 71.4 ± 11.6 0.79
Weight at end-of-trial (kg) 71.9 ± 14.4 71.2 ± 11.4 0.83
Weight change (kg) −0.4 ± 1.0 − 0.3 ± 1.2 0.53
BMI at study baseline (kg/m2) 27.2 ± 5.3 27.4 ± 4.0 0.84
BMI at end-of-trial (kg/m2) 27.0 ± 5.4 27.3 ± 3.9 0.80
BMI change (kg/m2) −0.2 ± 0.3 − 0.1 ± 0.4 0.49
MET-h/day at study baseline 27.5 ± 2.0 27.7 ± 2.1 0.60
MET-h/day at end-of-trial 27.6 ± 2.2 27.8 ± 2.3 0.69
MET-h/day change 0.1 ± 0.6 0.04 ± 1.0 0.83
Data are means± SDs
aObtained from independent t test. METs, metabolic equivalents
Table 2 Hormonal status, biomarkers of inflammation and oxidative stress at baseline and after the 12-week intervention in subjects
with polycystic ovary syndrome
Placebo group (n = 30) Synbiotic group (n = 30) pa
Baseline End-of-trial Change Baseline End-of-trial Change
Total testosterone (ng/mL) 2.4 ± 1.2 2.3 ± 1.0 −0.1 ± 0.5 2.8 ± 1.3 2.4 ± 0.9 −0.4 ± 0.9 0.09
SHBG (nmol/L) 38.3 ± 17.3 38.8 ± 17.6 0.5 ± 5.4 37.3 ± 13.1 57.1 ± 48.6 19.8 ± 47.3 0.01
FAI 0.27 ± 0.21 0.25 ± 0.16 −0.01 ± 0.08 0.33 ± 0.36 0.21 ± 0.14 −0.12 ± 0.29 0.01
mF-G scores 15.1 ± 3.8 15.0 ± 3.7 −0.1 ± 0.5 15.3 ± 5.6 14.0 ± 4.9 −1.3 ± 2.5 0.01
DHEAS (μg/mL) 2.6 ± 1.3 2.5 ± 1.1 −0.1 ± 0.4 2.6 ± 1.5 2.2 ± 0.8 −0.4 ± 1.1 0.40
hs-CRP (ng/mL) 2990.7 ± 2510.7 3326.0 ± 2791.1 335.3 ± 2466.9 2920.0 ± 2251.2 1970.0 ± 1442.0 −950.0 ± 2246.6 0.02
NO (μmol/L) 40.5 ± 8.7 40.8 ± 9.3 0.3 ± 9.1 39.0 ± 3.1 44.5 ± 5.0 5.5 ± 4.8 0.006
TAC (mmol/L) 868.7 ± 158.4 877.9 ± 149.9 9.2 ± 119.3 773.1 ± 38.7 818.2 ± 57.5 45.1 ± 51.8 0.13
GSH (μmol/L) 494.2 ± 85.5 521.5 ± 117.2 27.3 ± 117.8 498.9 ± 56.8 523.5 ± 53.4 24.7 ± 58.7 0.91
MDA (μmol/L) 2.2 ± 0.7 2.7 ± 1.2 0.5 ± 1.4 2.3 ± 0.4 2.1 ± 0.4 −0.2 ± 0.1 0.05
All values are means± SDs
aP values represent the time × group interaction (computed by analysis of the one-way repeated measures ANOVA)
DHEAS dehydroepiandrosterone sulfate, FAI free androgen index, GSH total glutathione, hs-CRP high-sensitivity C-reactive protein, mF-G modified Ferriman Gallwey,
MDA malondialdehyde, NO nitric oxide, SHBG sex hormone-binding globulin, TAC total antioxidant capacity
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synbiotic supplementation on other hormonal status and
biomarkers of oxidative stress.
Baseline levels of plasma TAC (p = 0.002) were signifi-
cantly different between the two groups. Therefore, we
controlled the analyses for the baseline levels, age and
baseline BMI. When we adjusted the analyses for base-
line values of biochemical variables, age and baseline
BMI, significant changes in FAI (p = 0.04) were observed,
but other findings did not alter (Table 3).
Discussion
In this research, which to our knowledge is the first of
its kind, we assessed the effects of synbiotic supplemen-
tation on hormonal, inflammatory and oxidative parame-
ters among subjects with PCOS. We shown that taking
synbiotic supplements for 12 weeks among PCOS sub-
jects had beneficial effects on SHBG, mFG scores, FAI,
serum insulin, HOMA-IR, serum hs-CRP and plasma
NO levels, but did not affect other hormonal, inflamma-
tory and oxidative parameters. However, observed reduc-
tion at mFG scores after 12 weeks was statistically
significant, it was clinically low. Long-term interventions
and higher dosage of probiotic and inulin might result in
greater changes in mFG scores.
Subjects with PCOS are susceptible to several metabolic
complications including insulin resistance and inflamma-
tion [25, 26]. We found that synbiotic administration for
12 weeks among PCOS subjects led to a significant in-
crease in serum SHBG values and FAI and a significant
decrease in mFG scores, serum insulin levels and HOMA-
IR, but did not affect hormonal profiles compared with
the placebo. However, to our knowledge, no reports are
available indicating the effects of synbiotic supplementa-
tion on hormonal status, biomarkers of inflammation and
oxidative stress in subjects with PCOS; some studies have
evaluated the effects of synbiotic supplementation on
markers of insulin metabolism among subjects without
PCOS. We have previously shown that taking synbiotic
supplements for 6 weeks among subjects with GDM had
beneficial effects on markers of insulin metabolism [5].
Shoaei et al. [27] also indicated that probiotic supplemen-
tation for 12 weeks to women with PCOS significantly de-
creased fasting glucose and insulin concentrations. In
another study conducted by Eslamparast et al. [28], it was
seen that levels of fasting glucose and insulin resistance
were improved significantly in the synbiotic group among
subjects with metabolic syndrome after 28 weeks. In
addition, the intake of synbiotic containing Lactobacillus
acidophilus, Bifidobacterium bifidum and fructo-
oligosaccharides in elderly people with T2DM resulted in
a significant reduction in fasting glycemia [29]. Hyperinsu-
linemia and insulin resistance in women with PCOS dir-
ectly stimulate ovarian steroidogenesis by acting on thecal
cell proliferation and increasing secretion of androgens
mediated by luteinizing hormone (LH), increased gene ex-
pression of cytochrome P450 and insulin-like growth fac-
tor 1 receptor [30]. In addition, androgens may regulate
follicular atresia [31]. It was also reported that increased
testosterone levels increase somatic cell atresia in rat ovar-
ies [32]. Furthermore, hyperandrogenemia can induce in-
flammation in women with PCOS [33]. Therefore,
synbiotic intake due to its useful effects on insulin resist-
ance may be useful to control clinical and metabolic
symptoms. Synbiotic intake might improve SHBG and
mFG scores through improved insulin sensitivity, the
modification of gut flora, the elevation of faecal pH [34]
and the reduction of pro-inflammatory cytokine produc-
tion [35].
Our previous study among subjects with T2DM has
demonstrated that consumption of a synbiotic food for
6 weeks had significant effects on serum hs-CRP con-
centrations [24]. In addition, supplementation with a
Table 3 Adjusted changes in metabolic profile of the patients with polycystic ovary syndrome
Placebo group (n = 30) Synbiotic group (n = 30) pa
Total testosterone (ng/mL) − 0.2 ± 0.1 − 0.3 ± 0.1 0.26
SHBG (nmol/L) 0.7 ± 6.1 19.5 ± 6.1 0.03
FAI −0.04 ± 0.02 −0.10 ± 0.02 0.04
mF-G scores −0.1 ± 0.3 −1.3 ± 0.3 0.007
DHEAS (μg/mL) −0.1 ± 0.1 −0.3 ± 0.1 0.18
hs-CRP (ng/mL) 375.6 ± 339.8 −990.2 ± 339.8 0.006
NO (μmol/L) 0.6 ± 1.2 5.2 ± 1.2 0.009
TAC (mmol/L) 23.8 ± 16.3 30.5 ± 16.3 0.78
GSH (μmol/L) 26.3 ± 15.8 25.7 ± 15.8 0.98
MDA (μmol/L) 0.4 ± 0.2 −0.1 ± 0.2 0.02
All values are means± SEs. Values are adjusted for baseline values, age and BMI at baseline
aObtained from ANCOVA
DHEAS dehydroepiandrosterone sulfate, FAI free androgen index, GSH total glutathione, hs-CRP high-sensitivity C-reactive protein, mF-G modified Ferriman Gallwey,
MDA malondialdehyde, NO nitric oxide, SHBG sex hormone-binding globulin, TAC total antioxidant capacity
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synbiotic among adults with nonalcoholic fatty liver dis-
ease over 28 weeks inhibited inflammatory markers [36].
Consumption of the synbiotic bread for 2 months in
people with T2DM significantly increased plasma levels
of NO and decreased MDA, but unchanged TAC, GSH,
catalase concentrations [9]. These findings were similar
in pregnant women [37] and patients with rheumatoid
arthritis [38]. Furthermore, soy milk containing probiotic
for 48 h increased NO production in human endothelial
cells [39]. A significant decline in MDA values was also
evidenced after the intake of probiotic in rabbits for
30 days [40]. However, synbiotic supplementation for
6 weeks did not influence CRP values [41]. In addition,
NO status did not affect by probiotic in herpes simplex
virus type 1 [42]. Supplementation with probiotic sup-
plements for 7 days did not decrease MDA values [43].
Elevated inflammatory markers in subjects with PCOS
would result in increased risk of atherosclerosis, diabetes
and infertility [44]. In addition, oxidative stress is corre-
lated with obesity and hyperandrogenism [45]. Increased
oxidative stress could also induce directly genetic vari-
ation by DNA damage, and epigenetic change including
elevated DNA methylation levels, which both play im-
portant roles in the pathogenesis of cancer [46, 47]. Up-
regulation of IL-18 by SCFA products [48] and elevated
production of methylketones in gut by synbiotic [49]
might decrease inflammatory markers. Decreased hydro-
peroxides by synbiotic intake may elevate NO levels [50,
51]. Moreover, synbiotic intake may reduce MDA be-
cause its impact on decreased lipid parameters [52] and
inhibiting lipid peroxidation reactions [53, 54].
Limitations of our study include the absent of testing
for a dose-response relationship between synbiotic in-
take and occurred changes in the metabolic profiles. Fur-
thermore, we did not determine the effects of synbiotic
on other metabolic parameters. However, duration of
the treatment was too short to determine the effects of
synbiotic on hormonal parameters and mFG scores; we
believe that future studies with cross-over design and
longer duration of the intervention are required to prove
our findings. Furthermore, the high standard deviations
(SDs) of dependent parameters in some cases might be
due to the small number of participants in the study.
Conclusions
Overall, synbiotic supplementation for 12 weeks in
PCOS women had beneficial effects on SHBG, mFG
scores, FAI, hs-CRP and NO levels, but did not affect
other hormonal status and biomarkers of oxidative
stress.
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